XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Operating Segments and Related Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedules of Concentration of Risk, by Risk Factor

The Company's revenue concentrations of 10% and greater were as follows:

															Three Months Ended March 31,
			Segment																		2024						2023
Customer A			Infrastructure																		27.6%						28.1%

Schedule of Company's Operating Segments

Summarized financial information with respect to the Company’s operating segments is as follows (in millions):

												Three Months Ended March 31,
																		2024						2023
Revenue
Infrastructure																		$	307.9					$	311.7
Life Sciences																		1.0						0.5
Spectrum																		6.3						5.7
Total revenue																		$	315.2					$	317.9

												Three Months Ended March 31,
																		2024						2023
Income (loss) from operations
Infrastructure																		$	9.3					$	6.3
Life Sciences																		(3.2)						(4.4)
Spectrum																		0.2						(0.5)
Other																		—						(1.4)
Non-Operating Corporate																		(3.5)						(4.0)
Total income (loss) from operations																		$	2.8					$	(4.0)

												Three Months Ended March 31,
																		2024						2023
Reconciliation of the consolidated segment income (loss) from operations to consolidated loss from operations before income taxes:
Income (loss) from operations																		$	2.8					$	(4.0)
Interest expense																		(17.2)						(15.6)
Loss from equity investees																		(1.2)						(4.0)
Other (expense) income, net																		(1.2)						16.5
Loss from operations before income taxes																		$	(16.8)					$	(7.1)

												Three Months Ended March 31,
																		2024						2023
Depreciation and Amortization
Infrastructure																		$	3.0					$	4.9
Infrastructure recognized within cost of revenue																		4.0						3.9
Total Infrastructure																		7.0						8.8
Life Sciences																		0.1						0.1
Spectrum																		1.3						1.3
Total depreciation and amortization																		$	8.4					$	10.2

												Three Months Ended March 31,
																		2024						2023
Capital Expenditures (*)
Infrastructure																		$	5.2					$	3.0
Life Sciences																		0.1						0.1
Spectrum																		0.3						0.3
Non-Operating Corporate																		—						0.3
Total																		$	5.6					$	3.7

(*) The above capital expenditures exclude assets acquired under finance lease and other financing obligations.

Schedule of Segment Reporting for Long-term investments, Property and Equipment - Net and Assets

			March 31, 2024						December 31, 2023
Investments
Life Sciences			$	1.8					$	1.8
Total			$	1.8					$	1.8

The Company's equity method investments in the Life Sciences segment included in the table above totaled $0.9 million as of both March 31, 2024 and December 31, 2023.

						March 31, 2024						December 31, 2023
Total Assets
Infrastructure						$	746.6					$	851.4
Life Sciences						8.2						8.3
Spectrum						175.5						176.6
Non-Operating Corporate						13.2						7.3
Total						$	943.5					$	1,043.6

X

- Definition

Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph b
-SubTopic 10
-Topic 280
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration